Literature DB >> 2582589

Inhibition of cardiac vagal effects by neurally released and exogenous neuropeptide Y.

M R Warner1, M N Levy.   

Abstract

Neuropeptide Y (NPY) attenuates vagal effects on cardiac cycle length, presumably by inhibiting the release of acetylcholine from vagal nerve endings. We sought to determine if NPY inhibited the vagal effects on atrioventricular (AV) interval and atrial contraction in a manner similar to its inhibition of the vagal effects on cycle length. In 19 anesthetized dogs we measured the vagal effects on cycle length, AV interval, and atrial contraction before and after 3-minute trains of sympathetic stimulation or before and after exogenous NPY (20 micrograms/kg i.v.). Three minutes after 10-Hz sympathetic stimulation, the vagal effects on cycle length and AV interval were attenuated by 52 +/- 9% and 63 +/- 8%, respectively. Phentolamine significantly augmented this attenuation, but propranolol had no appreciable effect. In the control group of animals or in the group that received phentolamine, the vagal effects on atrial contraction measured before and after sympathetic stimulation were not significantly different. In these two groups, however, the basal atrial contraction was reduced substantially after the cessation of sympathetic stimulation. Propranolol prevented this reduction in atrial contraction. After propranolol, the vagal effects on atrial contraction 3 minutes after sympathetic stimulation were attenuated by 31 +/- 6%. Exogenous NPY had no direct effect on cycle length, AV interval, or atrial contraction, but exogenous NPY did persistently inhibit the vagal effects on each of these cardiac processes. Three minutes after NPY was given, the vagal effects on cycle length, AV interval, and atrial contraction were inhibited by 62 +/- 7%, 69 +/- 5%, and 68 +/- 5%, respectively. We conclude that NPY attenuates the vagal effects on the atrial myocardium and on the sinus and AV nodes. In the absence of beta-blockade, the inhibitory effect of neurally released NPY on the vagally induced decreases in atrial contraction may be masked by the reduction in the atrial contraction that occurs after sympathetic stimulation.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2582589     DOI: 10.1161/01.res.65.6.1536

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  10 in total

Review 1.  Review article: heart rate and blood pressure control in vasovagal syncope.

Authors:  D G Benditt; W Fabian; D Iskos; K G Lurie
Journal:  J Interv Card Electrophysiol       Date:  1998-03       Impact factor: 1.900

Review 2.  Neuroendocrine changes in chronic cardiac failure.

Authors:  D P Nicholls; G N Onuoha; G McDowell; J S Elborn; M S Riley; A M Nugent; I C Steele; C Shaw; K D Buchanan
Journal:  Basic Res Cardiol       Date:  1996       Impact factor: 17.165

Review 3.  Peripheral cardiac sympathetic hyperactivity in cardiovascular disease: role of neuropeptides.

Authors:  Julia Shanks; Neil Herring
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2013-09-04       Impact factor: 3.619

4.  Heterogeneity of prejunctional NPY receptor-mediated inhibition of cardiac neurotransmission.

Authors:  A P Serone; C E Wright; J A Angus
Journal:  Br J Pharmacol       Date:  1999-05       Impact factor: 8.739

5.  Production, characterization, and expression of neuropeptide Y by human pheochromocytoma.

Authors:  P deS Senanayake; J Denker; E L Bravo; R M Graham
Journal:  J Clin Invest       Date:  1995-11       Impact factor: 14.808

6.  Inhibition of cardiac vagal action by galanin but not neuropeptide Y in the brush-tailed possum Trichosurus vulpecula.

Authors:  G P Courtice; E K Potter; D I McCloskey
Journal:  J Physiol       Date:  1993-02       Impact factor: 5.182

7.  Neuropeptide Y inhibits acetylcholine release in human heart atrium by activation of Y2-receptors.

Authors:  Eckhard Schwertfeger; Thomas Klein; Oliver Vonend; Vitus Oberhauser; Johannes Stegbauer; Lars Christian Rump
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-04-22       Impact factor: 3.000

8.  Effects of neuropeptide Y on L-type calcium current in guinea-pig ventricular myocytes.

Authors:  S M Bryant; G Hart
Journal:  Br J Pharmacol       Date:  1996-07       Impact factor: 8.739

Review 9.  Mechanisms underlying the autonomic modulation of ventricular fibrillation initiation--tentative prophylactic properties of vagus nerve stimulation on malignant arrhythmias in heart failure.

Authors:  Kieran E Brack; James Winter; G André Ng
Journal:  Heart Fail Rev       Date:  2013-07       Impact factor: 4.214

Review 10.  Autonomic control of the heart: going beyond the classical neurotransmitters.

Authors:  Neil Herring
Journal:  Exp Physiol       Date:  2014-11-20       Impact factor: 2.969

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.